Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hybrid-APC Margin Ablation to Prevent Post EMR Adenoma Recurrence

NCT04015765 is registered in ClinicalTrials.gov with Centre hospitalier de l'Université de Montréal (CHUM) as lead sponsor.

NCT NCT04015765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04015765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hybrid-APC Margin Ablation to Prevent Post EMR Adenoma Recurrence
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Phase
Not applicable
Overall status
Completed
Start date
August 26, 2019
Completion date
January 8, 2025
Enrollment
376 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, polyp of colon